ArticleMolecular cancer2023
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer.
Open access · goldAbstract read
In one paragraph
Article in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
15.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 102 citations in OpenAlex.
- Adenosine 5'-Carboxamide-Based Inhibitors of METTL1.ACS medicinal chemistry letters · 2026Article
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- METTL1/WDR4 Complex: A Novel Epitranscriptomic Target at the Crossroads of RNA Methylation and Drug Discovery.Journal of medicinal chemistry · 2026Review
- Transfer RNA Modifications in the Immune System Participate in Disease Pathogenesis.International journal of molecular sciences · 2026Review
- tRNA methylation: functional insights and epitranscriptomic regulation.Cell communication and signaling : CCS · 2026Review
- Article
- RNA methylation in cell death: mechanisms and clinical applications.Molecular cancer · 2026Review
- METTL1-mediated mOncogene · 2026Article
- G/C-ending and synonymous codon bias define functional translational programs that shape human tissue and cancer proteomes.NAR genomics and bioinformatics · 2026Article
- Expression, functional role, and mechanistic insights into tRF-His-GTG-008 in lung adenocarcinoma.World journal of surgical oncology · 2026Article
- tRNA modifications in cancer: from molecular mechanisms to clinical translation.Biomarker research · 2026Review
- METTL1 interacts with XPO5 to modulate pre-miRNA export.Nucleic acids research · 2026Article
- Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.Cancer cell · 2026Review
- Emerging roles of tRNA modification-mediated codon-specific translational reprogramming in cancer biology.Cell death & disease · 2026Review
- METTL1-Mediated NMedComm · 2026Article
- Integrated analysis of bulk RNA and single-cell RNA sequencing data reveals potential biomarkers and immune infiltrates associated with N7-methylguanosine in osteoarthritis.International journal of surgery (London, England) · 2026Article
- Transfer RNA expression, modification, and derived small RNAs in cancer biology and clinical potential.Frontiers in immunology · 2026Review
- RNA methylation in urological cancers: regulatory logic, biological functions, and clinical relevance.Frontiers in immunology · 2026Review
- N6-methyladenosine as a potential epitranscriptomic immune rheostat during SARS-CoV-2 infection.Frontiers in immunology · 2026Review
- RNA modifications: roles in immune cell biology and tumor regulation.Cancer cell international · 2025Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 17 institutions in 6 countries.
Raquel García-VílchezCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Ana M Añazco-GuenkovaCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Sabine DietmannWashington University School of Medicine in St. Louis, 660S. Euclid Ave, St. Louis, MO, 63110, USA.
Judith LópezCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Virginia Morón-CalventeCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Silvia D'AmbrosiPresent Address: Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV, Amsterdam, The Netherlands.
Paz NombelaCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Kepa ZamacolaCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Isabel MendizabalCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Saioa García-LongarteCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Amaia Zabala-LetonaCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Ianire AstobizaCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Sonia FernándezCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Alejandro PaniaguaCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Borja Miguel-LópezCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Virginie MarchandUniversité de Lorraine, UAR2008 IBSLor CNRS-UL-INSERM, Biopôle UL, 9, Avenue de La Forêt de Haye, 54505, Vandoeuvre-Les-Nancy, France.
Diego Alonso-LópezBioinformatics Unit, Cancer Research Center (CIC-IBMCC, CSIC/USAL), Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), 37007, Salamanca, Spain.
Angelika MerkelJosep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Barcelona, Catalonia, Spain.
Ignacio García-TuñónCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Aitziber Ugalde-OlanoDepartment of Pathology, Basurto University Hospital, 48013, Bilbao, Spain.
Ana Loizaga-IriarteCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Isabel Lacasa-ViscasillasDepartment of Urology, Basurto University Hospital, 48013, Bilbao, Spain.
Miguel UndaCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Mikel AzkargortaCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Félix ElortzaCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Laura BárcenaCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Monika Gonzalez-LopezCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Ana M AransayCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Tomás Di DomenicoBioinformatics Unit, Spanish National Cancer Research Centre (CNIO), 28029, Madrid, Spain.
Manuel A Sánchez-MartínInstituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.
Javier De Las RivasCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain.
Sònia GuilJosep Carreras Leukaemia Research Institute (IJC), Badalona, 08916, Barcelona, Catalonia, Spain.
Yuri MotorinUniversité de Lorraine, UAR2008 IBSLor CNRS-UL-INSERM, Biopôle UL, 9, Avenue de La Forêt de Haye, 54505, Vandoeuvre-Les-Nancy, France.
Mark HelmInstitute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Mainz, Germany.
Pier Paolo PandolfiMolecular Biotechnology Center (MBC), Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126, Turin, TO, Italy.
Arkaitz CarracedoCIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 801 Bld, 48160, Derio, Bizkaia, Spain.
Sandra BlancoCentro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC)-University of Salamanca, 37007, Salamanca, Spain. sandra.blanco@usal.es.
Association of Electronic and Information Technologies · ESCentro de Investigación del Cáncer · ESCIC bioGUNE · ESUniversidad de Salamanca · ESInstituto de Investigación Biomédica de Salamanca · ESDigital Research Alliance of CanadaHospital de Basurto · ESJosep Carreras Leukaemia Research Institute · ESBioCruces Health research Institute · ESCentro de Investigación Biomédica en Red de Cáncer · ESIkerbasque · ESIngénierie Moléculaire et Physiopathologie Articulaire · FRInserm · FRJohannes Gutenberg University Mainz · DESpanish National Cancer Research Centre · ESUniversity of Turin · ITWashington University in St. Louis · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N
Indexed as
CarcinogenesisProstatic NeoplasmsCell Transformation, NeoplasticHumansMaleMethyltransferasesRNA Processing, Post-TranscriptionalTranscription, GeneticMethyltransferasesMETTL1 protein, human7-methylguanosineEpitranscriptomeImmune checkpoint blockadeInterferonProstate cancerRNA modificationstRNA fragmentsTumour microenvironment (TME)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.